We describe how a single intraperitoneal injection of an indoline-derived drug (SN 28127) reduced mouse body weight (25-45% loss) and adipose tissue mass (B75%).
INTRODUCTION
Obesity and its associated comorbidities including type 2 diabetes (T2D) are one of the world's fastest-growing health challenges. 1 Efficacious and safe pharmacological treatments have yet to emerge. 2 The most successful anti-obesity drug treatments to date have resulted in only a modest 5-11% human body weight loss over 1 year, and all of these treatments except for orlistat (Xenical) have been withdrawn from the market owing to unwanted side effects. [3] [4] [5] Serendipitously, during toxicology testing of an indolinederived class of potential anticancer compounds (designed as prodrugs for release of a DNA alkylating agent in hypoxic tumor tissue), we discovered that female C3H/HeN mice shed 425% of their body weight over 3-4 weeks following a single intraperitoneal (i.p.) injection of the compound SN 28127 (for structure see Supplementary Figure S1 ). 6 Remarkably, these mice maintained reduced body weights for the length of the study (23 weeks) while appearing to eat normally and maintaining good health.
To investigate the mechanism for the drug-induced body weight reduction by this class of compounds, we here examine the effects of SN 28127 and an analog (SN 29220) on five different mouse strains; two with normal body weight (C3H/HeN and a/a), one with increased lean mass (NZG/Kgm), 7 one that is naturally obese with T2D (A VY /a) and one that is sensitive to developing obesity on a high-fat diet (C57Bl/6J). We compare metabolic phenotypes and gene expression patterns of mice following systemic (i.p.) dosing with SN 28127, SN 29220 or vehicle, and examine effects on reversal of high-fat diet-induced obesity and T2D. To explore the site of action of the drug, we also studied biodistribution of radiolabeled SN 29220 in mice.
MATERIALS AND METHODS

Mice and compounds
Male C3H/HeN, C57BL/6J, a/a, A VY /a and NZG/Kgm mice 7 were bred in the Vernon Jansen Animal Unit, University of Auckland. The University of Auckland Animal Ethics Committee approved the animal protocols, which permitted continuing observation of animals with severe body weight loss provided that daily monitoring of clinical signs indicated the animals to be in good general health. The animals were closely monitored daily for clinical signs of ill health. Up to four mice were housed per cage and the mice were provided with routine chow (Teklad Global 18% protein rodent diet purchased from Harlan Teklad Global Diets, Oxford, UK) or special lowand high-fat rodent diets (D12450B, 10 kcal% fat and D12451, 45 kcal% fat diets purchased from Research Diets Inc., New Brunswick, NJ, USA) and water ad libitum. The indoline-derived drugs SN 28127 and SN 29220 were synthesized as described 6 and formulated in dimethyl sulfoxide (DMSO)/ water (42:58v/v) for i.p. dosing at 1 ml g À 1 body weight.
Characterization of SN 28127 effects on C3H/HeN, a/a, A VY /a and NZG/Kgm mouse metabolic phenotypes, and gene expression at 160 days post drug injection Male mice (B40 days old; 3-5 mice per group) were housed individually for these experiments and had unrestricted access to normal chow and tap water. Body weight and food and water intake were monitored daily Monday through Friday for B160 days post SN 28127 (4.21 mmol kg À 1 ) or 42% DMSO (control) injections. At B160 days post injection, mice were euthanized, weighed, and body length (nose-anus) and tail length measured. Blood and organs were collected for blood biochemistry analyses, measurement of blood insulin and leptin, immunohistochemistry on white adipose tissues, in situ hybridization of AGRP, POMC and NPY messenger RNA (mRNA) expression in brain, and real-time PCR quantitation of expression of genes involved in fatty acid synthesis, fatty acid oxidation and thermogenesis on retroperitoneal fat, liver and skeletal muscle (see Supplementary methods).
Characterization of SN 28127 and SN 29220 drug-dose and timecourse responses on C3H/HeN mice The experimental protocols for these experiments conducted on B50-day-old male mice housed four per cage are described in the Supplementary data.
Characterization of SN 29220 effects on C3H/HeN mouse metabolic phenotype and gene expression at 2, 10, 30 and 160 days post drug injection
The experimental protocols for mouse handling, phenotypic analyses, realtime PCR and in situ hybridization are described in the Supplementary data.
Effect of SN 29220 on high-fat diet-induced obesity and high-fat diet-induced T2D in male C57B/6J mice The experimental protocols are described in the Supplementary data.
Distribution of radiolabeled SN 29220 in male C3H/HeN mouse blood, urine, feces and tissues The experimental protocols are described in the Supplementary data.
Effect of SN 29220 on urinary glucose and fecal triacylglycerol and cholesterol
The experimental protocols are described in the Supplementary data.
Statistics
GraphPad Prism version 4 (San Diego, CA, USA) was used to perform all statistical analyses. Data for body size and weight, organ and tissue weights, blood biochemistry, hormone levels and gene expression are shown as mean±s.e.m., and statistical analyses were performed using one-way or two-way analysis of variance followed by Bonferroni's post-hoc test. Data for urinary glucose and fecal fats were analyzed using unpaired Student's t-tests. For multiple comparisons, Kruskal Wallis and Dunn's or Mann-Whitney nonparametric tests were used. A P value o0.05 was considered statistically significant.
RESULTS
SN 28127 significantly reduced body weight of C3H/HeN mice and transiently increased food and water intake SN 28127 (4.21 mmol kg À 1 in 42% DMSO) reduced mouse body weight starting in the first week post drug injection and this reduction was sustained over the 160-day observation period (Figure 1 ). SN 28127 caused transient increases in both food and water intake between 10 and 110 days post drug injection and then returned to levels similar to control animals. By 160 days post DMSO or drug injection, the body lengths of C3H/HeN mice were significantly reduced (by 7%) compared with DMSO-treated control mice (Figure 1b Figure S3) . SN 28127 treatment significantly reduced the weights for the liver, kidneys, spleen, heart, stomach and brain compared with DMSOtreated controls for C3H/HeN mice, and similar changes, although not always significant, were observed for the other mouse strains (Supplementary Figures S4 and S5) . SN 28127 induced a significant increase in plasma albumin compared with DMSO-treated controls for C3H/HeN mice, but there were no significant differences for plasma sodium, potassium, total protein, alanine aminotransferase or aspartate aminotransferase (Figure 2 and Supplementary Figure S6) . In contrast, plasma alkaline phosphatase levels were significantly increased following SN 28127 treatments in C3H/HeN mice compared with DMSO-treated controls ( Figure 2 and Supplementary Figure S4 Characterization of the effects of SN 29220 treatment on C3H/HeN mouse metabolic phenotype at 10, 30, 50 and 160 days, and tissue-specific gene expression at 10 days post drug injection SN 29220 treatment decreased body weight, body length, and liver, retroperitoneal fat and gonadal fat weights compared with DMSOtreated control mice from post-injection days 22 through 50 ( Figure 4 ). These reductions were sustained through day 160 post drug injection as were reductions in kidney mass, plasma globulin, plasma amylase and plasma triacylglycerols (Supplementary Figures S11, S12, S13, S14 and S15 and Supplementary Table S1 Figure S11) . The reduction in spleen mass and increase in plasma albumin were sustained through 160 days post drug treatment (Supplementary Figures S12, S13 and S14). Plasma alanine aminotransferase and aspartate aminotransferase levels were significantly increased only at 22 and 30 days post SN 29220 Figure 3 . SN 28127 (a) and SN 29220 (b) reproducibly and dose dependently reduced body weight and transiently increased water intake without affecting food intake in B50-day-old male C3H/HeN mice. Animals were housed in groups of four, and at B50 days of age they were injected i.p. with either 42% aqueous DMSO or compound. Body weight and food and water intake were measured up to B60 days post injection and body weight data are shown as a percentage of the mouse body weight on the day of injection. Food and water intake are expressed as weight per mouse per day. Data are shown as mean (n ¼ 8 mice per treatment) for four and three independent pair-wise (DMSO/ SN 28127) and (DMSO/SN 29220) experiments, respectively. Error bars are omitted for clarity. ). Body weight, body length and tail length were measured when mice were euthanized and tissues were collected at the times post injection, indicated on the x axis. Data are shown as mean±s.e.m.; n ¼ 8. Mann-Whitney U-test; *Po0.05; **Po0.01; ***Po0.001. Figures S11, S12 , S13, S14, S15, S16, S17, S18 and S19). At 10 days post SN29220 treatment, a significant decrease in retroperitoneal CPT1 gene expression was observed compared with DMSO-treated control mice (Supplementary Figure S20) Figure S21) , skeletal muscle (Supplementary Figure S22) and hypothalamus (Supplementary Figure S23) . SN 29220 treatment reversed high-fat diet-induced obesity in male C57BL/6J mice The body weights of all SN 29220-treated mice on the high-fat diet decreased dose-dependently from B10-15 days post drug injection compared with DMSO-treated control mice. By B20 days post 1.4 mmol kg À 1 SN 29220 injection, the body weights of mildly obese mice were lower than those of age-matched DMSO-treated control mice on a low-fat diet, and B40 days post 0.47 mmol kg À 1 SN 29220 injection they had decreased to match those of the agematched DMSO-treated control mice on a low-fat diet (Figure 5a ). After B46 days post 1.4 mmol kg À 1 SN 29220 injection, the body weights of morbidly obese mice had reached the same body weights as those of the age-matched DMSO-treated control mice that fed a low-fat diet, and at B46 days post 0.47 mmol kg À 1 SN 29220 treatment, the average body weights of morbidly obese mice were markedly reduced compared with morbidly obese DMSO-treated mice (Figure 5b ). SN 29220 treatment had little effect on food intake when given to mildly obese mice but for the morbidly obese mice food intake was reduced by 15 days post drug treatment (Supplementary Figure S24) . SN 29220 treatment of either mildly or morbidly obese mice induced a dosedependent transient increase in water intake over B15-45 days post drug injection (Supplementary Figures S25) . SN 29220 (1.4 mmol kg À 1 ) reduced fat mass of morbidly obese mice by B75% at 42 days post drug treatment as shown by magnetic resonance imaging (Supplementary Figure S26) Figure S27) . SN 29220 treatment reversed high-fat diet-induced T2D in male C57BL/6J mice All DMSO-treated control mice on the high-fat diet had higher basal fasting blood glucose levels and increased area under the curves for both glucose tolerance tests (GTTs) and insulin tolerance tests compared with DMSO-treated control mice on the low-fat diet and SN 29220-treated mice on the high-fat diet. SN 29220 treatment completely reversed the insulin resistance in the mildly obese mice (Figure 6a) , and while the 30-min peak glucose in the GTT on the SN 29220-treated morbidly obese mice was intermediate between the DMSO-treated low-fat fed mice and the DMSO-treated high-fat fed mice, the blood glucose levels of the drug-treated mice were no different to the DMSO-treated, low-fat fed mice at 120 min after the GTT (Figure 6b ). Insulin induced a slow and sustained reduction in blood glucose in the SN 29220-treated mice on high-fat diet compared with both the DMSOtreated high-fat and low-fat fed control mice (Figure 6c ).
Distribution of radiolabeled SN 29220 in male C3HeN mice demonstrated that 5% of the radiolabel was still present in peripheral tissues 40 days post injection For the pilot study in which one mouse was studied per time point,B1, 60 and 65% of the radioactivity associated with the injected 3 H-SN 29220 was excreted in urine and feces at 4 h, 1 day and 3 days post dosing, respectively (Supplementary Figure S28) . After 4 h, relatively high levels of 3 H appeared in the bile, liver and ileum (Figure 7a ), consistent with biliary excretion as the major route of elimination. The levels of 3 H were considerably reduced 1 day post injection, but by day 9 post injection, relatively high levels of 3 H still remained in the spleen, pancreas and stomach compared with the other tissues. At all time points there was relatively little drug detected in the brain.
A larger study conducted with four mice per time point monitored 3 H in blood and organs for up to 40 days post injection. The radioactivity in blood was cleared almost completely by 40 days while many tissues showed significant retention of label, particularly the pancreas, spleen, liver, kidneys, stomach, visceral fat, retroperitoneal fat and gonadal fat (Figure 7b ). Again, little radioactivity was detected in the brain at any time point. SN 29220 treatment induced excessive urine excretion of glucose in male C57BL/6J mice Urine glucose levels were significantly elevated in male C57BL/6J mice at 59-64 days post SN 29220 treatment compared with DMSO-treated control mice (Table 1) . No significant differences were observed for urine and fecal weights, urine creatinine, fecal triacylglycerol and fecal cholesterol (Table 1) . Fasting blood glucose levels were significantly lower in the SN29920-treated mice compared with the DMSO-treated control mice (Table 1) .
DISCUSSION
We describe a dramatic drug-induced 25-45% mouse body weight loss, together with up to B75% fat mass loss, following treat- ment with the indoline-derived drugs SN 28127 and SN 29220. Remarkably, this followed a single i.p. injection of the compounds and was sustained up to 160 days post injection while the mice continued to eat similarly to control mice and displayed no abnormal clinical signs. Energy was lost in the urine of drugtreated mice as their urinary glucose levels were significantly elevated by B300-fold at B60 days post injection compared with control mice.
The drug-induced reduction in body weight and transient increase in thirst were dependent on the dose of SN 28127 or SN 29220 injected (Figure 3) . The body weight loss appeared to be greatest around 25 days post drug injection and thereafter body weight remained relatively stable. The drug-induced weight loss was largely due to a 51-78% loss of body fat (Figure 1) . Several organ weights were also significantly reduced (Supplementary Figure S4) following SN 28127 treatment, and while some of this organ weight loss was no doubt owing to the loss of specific organ-associated fat (for example, fat in the liver), other organ weight loss likely reflects the drug-induced reduction in body growth as these mice were young adults and still growing at the time of the drug injection. The rise in plasma albumin observed at 22 and 30 days post SN 29220 treatment may have contributed to the drug-related increased thirst that occurred at B15-40 days post injection in these mice (Figure 3b ). Increased sodium, decreased chloride and decreased potassium would be expected if an animal was dehydrated. These electrolyte changes were observed only during the period of increased thirst. The upregulation of fatty acid synthesis gene expression in retroperitoneal fat and liver, and the upregulation of AGRP mRNA and downregulation of POMC mRNA in the hypothalamus observed at 160 days but not at 10 days post drug treatment are likely adaptive changes to the reduced mouse body weight and fat mass. Future experiments, including knockdown of gene expression, are required to determine if these are important adaptive changes for maintenance of a reduced steady-state body weight.
Plasma leptin levels were significantly reduced by 79-88% by SN 28127 in all four strains of mice, which is likely attributed to the 51-78% drug-induced reductions in the masses of the three adipose tissues measured and further loss of other adipose tissue including subcutaneous fat. 8 The drug-induced decreased body weight and fat mass can be explained by the excessive amount of glucose excreted in the urine. Food intake and excretion of fecal fats were similar between the drug-treated and DMSO-treated control mice. We did not have the resources to measure energy expenditure and therefore do not know whether increased energy expenditure is also contributing to the weight loss.
The mice injected with SN 29220 had significantly decreased plasma amylase levels at 22-160 days post drug injection compared with DMSO-treated control mice, indicating that they could have developed chronic pancreatitis (Supplementary Figure S13) . Scarring in the head of the pancreas occurs in chronic pancreatitis and this prevents bile draining from the liver to the duodenum. Plasma ALP levels, used as a measure of the integrity of the hepatobiliary system and the flow of bile into the small intestine, were significantly increased in the SN 29220-treated C3H/HeN mice at 30, 50 and 160 days post drug treatment compared with DMSO-treated control mice (Supplementary Figures S11 and S16 ) and they were also increased in the four strains of mice at 160 days following SN 28127 treatment compared with DMSO-treated control mice (Supplementary Figure S4) . This suggests that the hepatobiliary system was not functioning normally as early as 30 days after drug injection and this was sustained until 160 days.
Excessive glucose excretion and a dysfunctional hepatobiliary system could explain the drug-induced decreases in plasma Figure 6 . SN 29220 reversed high-fat diet-induced T2D in male C57BL/6J mice. Animals were housed in groups of four, and from weaning (21 days) they were fed either low-fat (10 kcal %fat) or highfat (60 kcal %fat) diets. (a) Mild Obese Model: mice on a high-fat diet were injected i.p. with either 42% aqueous DMSO (n ¼ 3) or SN 29220 (n ¼ 3) at B80 days of age. Control mice on a low-fat diet were injected i.p. with 42% aqueous DMSO (n ¼ 2), (b, c) Morbid Obese Model: mice on a high-fat diet were injected i.p. with either 42% aqueous DMSO (n ¼ 3) or SN 29220 (n ¼ 3) at B120 days of age. Control mice on a low-fat diet were injected i.p. with 42% aqueous DMSO (n ¼ 3). Between 46 and 53 days post injection, glucose tolerance tests (a and b) and insulin tolerance tests (c) were performed on mice after an overnight (16 h cholesterol and triacylglycerols at 22 and 30 days post drug treatment. While the reduction in plasma triacylglycerols was sustained until 160 days post drug treatment, the plasma cholesterol and HDL cholesterol levels were increased at 50 and at 160 days, compared with the DMSO-treated control mice. These increases may be an adaptive response to the drug-induced body and fat weight loss as there was a significant increase in hypothalamic AGRP mRNA expression in C3H/HeN mice at B160 days following SN 28127 drug treatment compared with DMSO-treated control mice. AGRP inhibits the central melanocortin system, and inhibition of this system was recently found to increase circulating HDL cholesterol by reducing its uptake by the liver, independent of food intake or body weight. 9 Retroperitoneal fat and spleen mass were significantly decreased by 10 days post SN 29220 treatments compared with DMSO-treated control mice and this was before a significant reduction in body weight was observed. An early response to SN 29220 that might explain the early reduction in retroperitoneal and spleen masses could be a transient inhibition of liver cholesterol uptake as HDL cholesterol was increased at 2 days post drug treatment. The prolonged reduction in plasma triacylglycerols likely accounts for the marked reductions in fat mass and body weight observed in the drug-treated mice, but this would not explain the significant loss of spleen mass. Adipose tissue is dynamically linked with the immune system, and recently eosinophil cells, which make up o3% of the white blood cells, were discovered to have an important role in metabolic homeostasis with a reciprocal relationship between eosinophil numbers and adipose tissue mass in mice. 10 Although we did not detect any abnormalities in spleen cell and tissue morphology (see Supplementary data), it is possible that an increase in eosinophil migration into adipose tissue and/or an increase in the numbers of eosinophils in the circulation contributes to the drug-induced reduction in both adipose tissue and spleen mass, as the spleen contributes to the production and storage of blood cells. 11 Tissue distribution of 3 H-SN 29220 is compatible with the hepatic system being the primary target for SN 29220. While radioactivity decreased over time in the liver, pancreas, bile duct, stomach and kidneys, the lipophilic drug was retained in the spleen, visceral fat and retroperitoneal fat up to B30 days after the injection of the drug. This retention of the lipophilic drug could produce toxic effects specific to these tissues given that they were the most sensitive to the drug-induced weight loss (Supplementary Figures 1, 4 and S13).
SN 29220 reversed obesity and T2D in both mildly and morbidly obese C57BL/6J mice that fed a high-fat diet (Figures 5 and 6 ). The reduction in body weight for the mild obesity model plateaued for both the low-and high-drug doses tested while the mice continued to eat a high-fat diet. Fat loss was clearly demonstrated in the drug-treated mice compared with age-matched DMSOtreated control mice in our magnetic resonance images (Supplementary Figure S26 ) and in our hematoxylin and eosinstained adipose tissue sections (Supplementary Figure S27) . Basal fasting plasma glucose levels in the drug-treated mice that fed a high-fat diet were reduced to levels close to those of the DMSOtreated control mice, and the GTTs showed that SN 29220 treatment reversed the insulin resistance. The insulin tolerance tests on SN 29220-treated morbidly obese mice produced an unexpected result. In contrast to the DMSO-treated control mice on either a high-fat or low-fat diet, the SN 29220-treated mice on the high-fat diet showed a slow decrease in plasma glucose levels following the insulin injection followed by a minimal rebound, even at 180 min after insulin injection. These data indicate that the drug-treated mice were less able to produce hepatic glucose in response to a low blood glucose level.
SN 28127 and SN 22920 are not potential clinical candidates for the treatment of obesity as they produce chronic toxicity and they possess an inherent DNA alkylating capability that is required to effectively reduce mouse body weight. 6 The real value of this serendipitous discovery that a single injection of a drug of this class can reduce body weight lies in understanding the drug target and its mechanism of action. The initial chronic toxicity (rapid weight loss and increased thirst) observed with these indoline-derived drugs is similar, although milder, than that observed following streptozotocin treatment of mice.
12,13 When we compared streptozotocin treatment alongside treatments with indoline-derived drugs, we had to euthanize all of the streptozotocin-treated mice 18 days post injections owing to ill health and diabetes mellitus. 6 In contrast to streptozotocin treatment, mice adapt to the indoline-derived drug treatment with a new reduced steady-state body weight. We hypothesize that the drugs reduce fat mass by primarily targeting the hepatic system, resulting in inhibition of hexokinase, excessive energy loss in the form of urinary glucose and reduced calories available for fat storage. The animals then adapt to this reduced fat mass and establish a new steady-state body weight. This adaptive mechanism may involve the hepatic AMPK-SRC2 axis that resets whole-body energy homeostasis by promoting absorption of dietary fat from the gut.
14 Future studies should determine whether indoline-derived drugs affect hexokinase activity and intestinal fat absorption.
